Regenics AS Welcomes Jostein Grip as CEO to Lead Wound Healing Innovations

Regenics AS Welcomes Jostein Grip as New CEO

Regenics AS, an emerging name in the Norwegian biotechnology scene, has officially announced the appointment of Jostein Grip as its new Chief Executive Officer effective August 1, 2025. Based in Oslo, this private company is renowned for its focus on advancing wound healing products, and with Grip at the helm, it aims to further enhance its innovation trajectory.

Grip is not new to the field of biotechnology. His academic background is robust; he holds a PhD from the University of Tromsø, where his research concentrated on pioneering wound dressings utilizing soluble beta-glycan (SBG®). This foundation in advanced research methodologies sets a solid base for his new role at Regenics, where he will immediately join a team focused on developing next-generation healthcare solutions.

Prior to joining Regenics, Grip served as Chief Technology Officer (CTO) at Oxy Solutions. His leadership experience in creating wound care products at Oxy Solutions aligns seamlessly with Regenics' mission. Jan A. Alfheim, Chair of the Board at Regenics, expressed confidence in Grip, stating, "Jostein is an excellent choice for the CEO role and that he will be a strong addition to the Regenics team. His expertise and knowledge in wound healing product development will be pivotal as we continue the advancement of our flagship product, Collex™."

Collex® is positioned as a revolutionary advanced wound dressing designed specifically to treat partial thickness burns and chronic wounds, including diabetic ulcers and chronic vascular ulcers. The product aims to set new standards in wound treatment by focusing on efficacy and patient outcomes. One of its unique attributes lies in its formulation; Collex® is produced with all-marine ingredients from the Norwegian coast, emphasizing both sustainability and local sourcing.

A significant component of Collex® is HTX™, which is derived from purified unfertilized salmon roe. This innovation not only showcases the practicality of using native resources but also highlights Regenics' commitment to employing environmentally friendly practices.

As the company embarks on its next stage of development, Grip's arrival represents a strategic move to ensure that Collex® meets its potential in clinical applications. Currently, the product is in late pre-clinical stages, demonstrating significant beneficial effects on wound healing rates. Through focused research and development initiatives, Regenics aims to bring Collex® to market, where it can make a meaningful impact in the field of wound care.

Karin Gilljam, who has been serving as the interim CEO, will transition back to her original role as Chief Scientific Officer (CSO). She will work closely with Grip, further strengthening the leadership team's expertise in the biotech sector. Gilljam has been integral to the company’s operations during the transitional phase and will continue to play a crucial role in the development of Regenics’ product lines.

With Grip’s extensive background in the biotechnology arena and his commitment to innovation, Regenics AS is well-positioned to make substantial strides in the field of wound care. The board of directors has also publicly acknowledged Gilljam's contributions, reinforcing the company's culture of appreciation and teamwork.

As the global demand for effective wound healing solutions grows, the strategic direction set by Grip may very well place Regenics AS among the leaders in the biotechnology industry. As stakeholders and the medical community look closely at the developments within the company, all eyes will be on how Grip and his team navigate the challenges ahead for the successful launch of Collex® and potentially redefine wound care standards across healthcare systems.

In conclusion, Jostein Grip's appointment as CEO brings renewed optimism to Regenics AS. With a legacy of innovation and a dedication to sustainable practices, the company is about to embark on a transformative journey under his leadership, focusing on enhancing the quality of life for patients requiring advanced wound care interventions.